Targets › PDCD1LG1
12 programs from 12 companies in 15 trials: 11 Phase 2, 2 Phase 1, 1 Phase 3, 1 Phase 4; Oncology, Infectious disease; next expected readout Dec 2026.
Plays a critical role in induction and maintenance of immune tolerance to self. As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response. (UniProt, Q9NZQ7)
Open in Phaseline: the race on PDCD1LG1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| The Second Affiliated Hospital of Chongqing Medical University | ASC22 PD-L1 inhibitor | PDCD1LG1 | Phase 4 | Chronic Hepatitis b | Dec 2026 |
| Pfizer | PF-08046054 Anti-PD-L1 antibody-drug conjugate | PDCD1LG1 | Phase 3 | Non-small Cell Carcinoma | Mar 2028 |
| Chia Tai Tianqing Pharmaceutical Group | TQB2450 injection humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1) | PDCD1LG1 | Phase 2 | Non Small Cell Lung Cancer | Dec 2026 |
| Shanghai Pulmonary Hospital, Shanghai, China | Envolizumab PD-L1 antibody | PDCD1LG1 | Phase 2 | Thymic Carcinoma | Dec 2026 |
| Sir Run Run Shaw Hospital | Icaritin Downregulates TNF-α, IL-6, and PD-L1 expression; reduces MDSC proportion to modulate tumor | TNF, IL6, PDCD1LG1 | Phase 2 | Advanced Pancreatic Ductal Adenocarcinoma | Apr 2027 |
| ImmunityBio | PD-L1 t-haNK PD-L1-targeted human aNK cell therapy | CD274, PDCD1LG1 | Phase 2 | Pancreatic Cancer; Non-Small Cell Lung Cancer; Glioblastoma; Head and Neck Cancer | May 2027 |
| Hebei Medical University Fourth Hospital | Adebrelizumab PD-L1 inhibitor | PDCD1LG1 | Phase 2 | Squamous Oesophageal Cancer | Sep 2027 |
| Hong Qiu | SHR-1701 Anti-PD-L1 monoclonal antibody | PDCD1LG1 | Phase 2 | CRC (Colorectal Cancer) | Dec 2027 |
| University Medical Center Groningen | 89Zr-atezolizumab PET-imaging PD-L1 imaging with radiolabeled anti-PD-L1 antibody | PDCD1LG1 | Phase 2 | Large B-cell Lymphoma | – |
| Yongxu Jia | TQB2450 PD-L1 inhibitor (monoclonal antibody) | PDCD1LG1 | Phase 2 | Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma | – |
| MediLink Therapeutics (Suzhou) | Ivonescimab (AK112) Bispecific antibody targeting PD-L1 and CTLA-4 | PDCD1LG1, PDCD1LG2 | Phase 1 | Advanced Solid Tumors | Jan 2027 |
| Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | DCR-PDL1 PDL1 inhibitor delivered via RNAi | PDCD1LG1 | Phase 1 | Solid Tumors, Adult | Dec 2027 |
Large B-cell Lymphoma (1) CRC (Colorectal Cancer) (1) Advanced Pancreatic Ductal Adenocarcinoma (1) Pancreatic Cancer (1) Non-Small Cell Lung Cancer (1) Glioblastoma (1) Head and Neck Cancer (1) Advanced Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma (1) Solid Tumors, Adult (1) Non Small Cell Lung Cancer (1) Squamous Oesophageal Cancer (1) Non-small Cell Carcinoma (1)
small molecule (6), mixed (3), antibody (1)
University Medical Center Groningen (1) Hong Qiu (1) Sir Run Run Shaw Hospital (1) ImmunityBio (1) Yongxu Jia (1) Dicerna Pharmaceuticals, Inc., a Novo Nordisk company (1) Chia Tai Tianqing Pharmaceutical Group (1) Hebei Medical University Fourth Hospital (1) Pfizer (1) Shanghai Pulmonary Hospital, Shanghai, China (1) The Second Affiliated Hospital of Chongqing Medical University (1) MediLink Therapeutics (Suzhou) (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.